Bogdan Bjelica

Dr. Bogdan Bjelica

Department of Neurology, Hannover Medical School, Hanover, Germany
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2024 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
Bogdan BjelicaBogdan Bjelica
Bogdan Bjelica
MBMaj-Britt Bartels
Maj-Britt Bartels
JHJasper Hesebeck-Brinckmann
Jasper Hesebeck-Brinckmann
SPSusanne Petri
Susanne Petri
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive degeneration of both upper and lower motor neurons. A defining histopathological feature in approximately 97% of all ALS cases is the accumulation of phosphorylated trans-activation response (TAR) DNA-binding protein 43 protein (pTDP-43) aggregates in the cytoplasm of neurons and glial cells within the central nervous system. Traditionally, it was believed that the accumulation of TDP-43 aggregates and subsequent neurodegeneration primarily occurs in motor neurons. However, contemporary evidence suggests that as the disease progresses, other systems and brain regions are also affected. Despite this, there has been a limited number of clinical studies assessing the non-motor symptoms in ALS patients. These studies often employ various outcome measures, resulting in a wide range of reported frequencies of non-motor symptoms in ALS patients. The importance of assessing the non-motor symptoms reflects in a fact that they have a significant impact on patients’ quality of life, yet they frequently go underdiagnosed and unreported during clinical evaluations. This review aims to provide an up-to-date overview of the current knowledge concerning non-motor symptoms in ALS. Furthermore, we address their diagnosis and treatment in everyday clinical practice.

30 October 2017 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
IBIvo Bozovic
Ivo Bozovic
AKAleksandra Kacar
Aleksandra Kacar
SPStojan Peric
Stojan Peric
ANAna Nikolic
Ana Nikolic
Bogdan BjelicaBogdan Bjelica
Bogdan Bjelica
IBIvana Basta
Ivana Basta

29 July 2017 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
SPStojan Peric
Stojan Peric
RMRuzica Maksimovic
Ruzica Maksimovic
BBBojan Banko
Bojan Banko
MDMilica Durdic
Milica Durdic
Bogdan BjelicaBogdan Bjelica
Bogdan Bjelica
VRVidosava M. Rakocevic-Stojanovic
Vidosava M. Rakocevic-Stojanovic

15 November 2019 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
Bogdan BjelicaBogdan Bjelica
Bogdan Bjelica
SPStojan Peric
Stojan Peric
IBIvana Basta
Ivana Basta
IBIvo Bozovic
Ivo Bozovic
AKAleksandra Kacar
Aleksandra Kacar
VSVidosava Rakocevic Stojanovic
Vidosava Rakocevic Stojanovic

1 August 2018 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
ZVZoran Vukojevic
Zoran Vukojevic
AKAleksandra Dominovic Kovacevic
Aleksandra Dominovic Kovacevic
SPStojan Peric
Stojan Peric
SGSanja Grgic
Sanja Grgic
Bogdan BjelicaBogdan Bjelica
Bogdan Bjelica
DLDragana Lavrnic
Dragana Lavrnic

17 February 2024 in BMC Neurology
Verified
Journal Article
Open access
PDF file
Bogdan BjelicaBogdan Bjelica
Bogdan Bjelica
CWCamilla Wohnrade
Camilla Wohnrade
ICIraima Cespedes
Iraima Cespedes
AOAlma Osmanovic
Alma Osmanovic
OSOlivia Schreiber-Katz
Olivia Schreiber-Katz
SPSusanne Petri
Susanne Petri
Background: We aimed to describe the experience of a single neuromuscular center in Germany in treating adult spinal muscular atrophy (SMA) patients with risdiplam and to analyze motor function and treatment satisfaction during a follow-up period up to 20 months. Methods: Fourteen patients with type 2 or 3 SMA (seven with SMA type 2, six with SMA type 3; age range: 18–51) were included. The Revised Upper Limb Module (RULM) and the Hammersmith Functional Motor Scale Expanded (HFMSE) were recorded at baseline and at follow-up (month 4, 8, 12, 16, 20). Treatment adverse events were collected at every follow-up visit. Patients’ treatment satisfaction was assessed by the Treatment Satisfaction Questionnaire for Medication (TSQM). Results: Half of the patients reached the 20-month follow-up. Based on the HFMSE score, no patients had clinically meaningful improvement. Twelve remained stable (92.3%), two showed transient clinically meaningful deterioration (15.4%) and one experienced lasting clinically meaningful deterioration (7.7%). Based on the RULM scores, seven patients were either stable or demonstrated clinically meaningful improvement (53.8%) and six showed clinically meaningful deterioration (46.2%). There was no treatment withdrawal during the follow-up. The most common adverse events were skin rash/increased skin sensitivity to sunlight (n = 3), diarrhea (n = 3), aphthous ulcer (n = 3) and abdominal pain (n = 2). Most patients stated to be at least “satisfied” with the medication. Conclusions: Risdiplam was well tolerated. Half of the patients remained stable or improved after risdiplam initiation. Larger and multicentric studies are needed to better understand the long-term effects of risdiplam in adult SMA.